DK3444010T3 - Pklr-inhibering i behandlingen af nafld og hcc - Google Patents

Pklr-inhibering i behandlingen af nafld og hcc Download PDF

Info

Publication number
DK3444010T3
DK3444010T3 DK17186181.8T DK17186181T DK3444010T3 DK 3444010 T3 DK3444010 T3 DK 3444010T3 DK 17186181 T DK17186181 T DK 17186181T DK 3444010 T3 DK3444010 T3 DK 3444010T3
Authority
DK
Denmark
Prior art keywords
pklr
nafld
hcc
inhibition
treatment
Prior art date
Application number
DK17186181.8T
Other languages
English (en)
Inventor
Adil Mardinoglu
Jan Borén
MATHIAS UHLéN
Original Assignee
Scandiedge Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scandiedge Therapeutics Ab filed Critical Scandiedge Therapeutics Ab
Application granted granted Critical
Publication of DK3444010T3 publication Critical patent/DK3444010T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/0104—Pyruvate kinase (2.7.1.40)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17186181.8T 2017-08-14 2017-08-14 Pklr-inhibering i behandlingen af nafld og hcc DK3444010T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17186181.8A EP3444010B1 (en) 2017-08-14 2017-08-14 Pklr inhibition in the treatment of nafld and hcc

Publications (1)

Publication Number Publication Date
DK3444010T3 true DK3444010T3 (da) 2021-03-15

Family

ID=59683407

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17186181.8T DK3444010T3 (da) 2017-08-14 2017-08-14 Pklr-inhibering i behandlingen af nafld og hcc

Country Status (7)

Country Link
US (1) US11034960B2 (da)
EP (2) EP3444010B1 (da)
CN (1) CN111093677A (da)
AU (1) AU2018317785B2 (da)
CA (1) CA3071350A1 (da)
DK (1) DK3444010T3 (da)
WO (1) WO2019034657A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200157541A1 (en) * 2018-11-19 2020-05-21 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency
JP2023537798A (ja) 2020-03-19 2023-09-06 アビディティー バイオサイエンシーズ，インク． 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
EP4134077A1 (en) * 2021-08-13 2023-02-15 ScandiEdge Therapeutics AB Small molecule treatment of fatty liver disease and hcc
KR20240055874A (ko) 2021-09-16 2024-04-29 어비디티 바이오사이언시스 인크. 안면견갑상완 근이영양증을 치료하는 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149379A2 (en) * 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
WO2011115810A2 (en) * 2010-03-16 2011-09-22 Massachusetts Institute Of Technology Isoform-specific rnai based on codon redundancy/degeneracy

Also Published As

Publication number Publication date
AU2018317785B2 (en) 2024-05-30
AU2018317785A1 (en) 2020-02-20
CA3071350A1 (en) 2019-02-21
EP3668523B1 (en) 2023-01-11
EP3444010A1 (en) 2019-02-20
US20200190523A1 (en) 2020-06-18
EP3444010B1 (en) 2020-12-09
WO2019034657A1 (en) 2019-02-21
US11034960B2 (en) 2021-06-15
CN111093677A (zh) 2020-05-01
EP3668523A1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3129018T3 (da) Behandling af NAFLD og NASH
DK3842429T3 (da) Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer
DK3322425T3 (da) Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
DK3134125T3 (da) Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3454844T3 (da) Behandling af tyktarmskræft med en kombination af hdac-inhibitoren hbi-8000 og en pd-l1-inhibitor
DK3612517T3 (da) Bicykliske forbindelser og deres anvendelse ved behandling af cancer
DK3371152T3 (da) Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer
MA49715A (fr) Oligomères et conjugués d'oligomères
DK3273995T3 (da) Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion
DK3432899T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3197429T3 (da) Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
DK3356444T3 (da) Med silikoneharpiks modificerede isocyanatoalkylalkoxysilan-addukter og deres anvendelse
DK3387156T3 (da) Lactobacillus casei til behandling af fedme og associerede metabolske sygdomme
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK3258964T3 (da) Detektion og behandling af maligne tumorer i CNS
DK3619362T3 (da) Forbedringer af og i forbindelse med barrierer
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3722291T3 (da) Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme
DK3444010T3 (da) Pklr-inhibering i behandlingen af nafld og hcc
DK3174559T3 (da) Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer